Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joshua Wharton

Dermatology Guntersville, AL Medical Doctor

NPI 1003014762 CMS profile 24

2307 Homer Clayton Dr, Guntersville, AL 35976

Open in the dashboard

General payments

$18,702

910 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Joshua Wharton of Guntersville, AL is reported in the CMS Open Payments database as having received $18,702 across 910 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,514 183
2024 General $3,415 170
2023 General $3,391 146
2022 General $2,666 129
2021 General $2,215 116
2020 General $1,816 82
2019 General $1,685 84

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joshua Wharton
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Joshua Wharton were reported at $3,514. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Joshua Wharton Dermatology median Middle half National median
2019 $1,685 $454 $129–$1,240 $163
2020 $1,816 $235 $81–$756 $114
2021 $2,215 $377 $108–$1,108 $132
2022 $2,666 $514 $143–$1,391 $149
2023 $3,391 $607 $159–$1,674 $160
2024 $3,415 $751 $204–$1,903 $164
2025 $3,514 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $5,318 250 payments
  2. Novartis Pharmaceuticals Corporation $2,296 129 payments
  3. Genzyme Corporation $1,501 66 payments
  4. Regeneron Healthcare Solutions, Inc. $1,025 48 payments
  5. Janssen Biotech, Inc. $877 40 payments
  6. E.R. Squibb & Sons, L.L.C. $855 42 payments
  7. Lilly USA, LLC $855 45 payments
  8. Pfizer Inc. $726 43 payments
  9. LEO Pharma Inc. $679 34 payments
  10. Dermavant Sciences, Inc. $605 19 payments
  11. Other $3,967 194 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $18,340 903 payments
  2. Education $295 6 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $68 1 payment
Products named General payments · program years 2019–2025
  1. RINVOQ $2,433 108 payments
  2. SKYRIZI $2,129 102 payments
  3. DUPIXENT Immunology $1,333 58 payments
  4. HUMIRA $929 39 payments
  5. DUPIXENT Inflammation And Immunology $851 37 payments
  6. COSENTYX Immunology $842 47 payments
  7. SOTYKTU $830 41 payments
  8. COSENTYX Dermatology $750 52 payments
  9. VTAMA $732 20 payments
  10. TALTZ $671 38 payments
  11. Other $9,018 466 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

1,182

Median for Dermatology: 534

Drug cost

$689,545

Median for Dermatology: $67,151

Branded share of claims

18.9%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 58 $214,870
Rinvoq Upadacitinib Brand 26 $201,066
Dupixent Syringe Dupilumab Brand 31 $140,008
Humira(Cf) Pen Adalimumab Brand 13 $87,332
Clobetasol Propionate Generic 130 $9,904
Fluorouracil Generic 69 $5,398
Acitretin Generic 12 $4,848
Betamethasone Dipropionate Generic 72 $3,606
Metronidazole Generic 39 $2,578
Ketoconazole Generic 98 $2,445

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 70 billing codes

Paid by Medicare

$436,708

Of which drugs: $17,898

Medicare patients

922

Average age 77

Services billed

20,110

446 women, 476 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Ischemic heart disease 34%
Diabetes 31%
Chronic kidney disease 26%
Atrial fibrillation 22%
Cancer 17%
COPD 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg J7345 Office 32 13,800 $17,893

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
$617 26 —
DUPIXENT
$529 89 —
VTAMA
$336 — —
SOTYKTU
$311 — —
COSENTYX
$254 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

910 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record